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Background Despite earlier doubts, a string of recent successes indicates that
if sample sizes are large enough, it is possible—both in theory and
in practice—to identify and replicate genetic associations with
common complex diseases. But human genome epidemiology is
expensive and, from a strategic perspective, it is still unclear what
‘large enough’ really means. This question has critical implications
for governments, funding agencies, bioscientists and the tax-paying
public. Difficult strategic decisions with imposing price tags and
important opportunity costs must be taken.
Methods Conventional power calculations for case–control studies dis-
regard many basic elements of analytic complexity—e.g. errors in
clinical assessment, and the impact of unmeasured aetiological
determinants—and can seriously underestimate true sample size
requirements. This article describes, and applies, a rigorous simula-
tion-based approach to power calculation that deals more compre-
hensively with analytic complexity and has been implemented on the
web as ESPRESSO: (www.p3gobservatory.org/powercalculator.htm).
Results Using this approach, the article explores the realistic power profile of
stand-alone and nested case–control studies in a variety of settings
and provides a robust quantitative foundation for determining the
required sample size both of individual biobanks and of large disease-
based consortia. Despite universal acknowledgment of the impor-
tance of large sample sizes, our results suggest that contemporary
initiatives are still, at best, at the lower end of the range of desirable
sample size. Insufficient power remains particularly problematic for
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263studies exploring gene–gene or gene–environment interactions.
Discussion Sample size calculation must be both accurate and realistic, and we
must continue to strengthen national and international cooperation
in the design, conduct, harmonization and integration of studies in
human genome epidemiology.
Keywords Human genome epidemiology, biobank, sample size, statistical
power, simulation studies, measurement error, reliability, aetiologi-
cal heterogeneity
Introduction
By 2020, common chronic diseases will account for
almost three-quarters of deaths worldwide.
1 The quest
to find genetic variants underlying these disorders
is in a ‘fast-moving, exciting and highly productive
phase’.
2 If the common disease common variant
hypothesis
3–8 is true for at least some genetic deter-
minants of chronic diseases, their aetiological effects
will typically be weak
9,10 and they will be identified
more readily by association rather than linkage
studies.
11 In consequence, although alternative stra-
tegies could have been adopted,
12 the majority of
contemporary gene discovery studies are based on
association studies in unrelated individuals.
A series of recent publications has convincingly
identified or replicated genetic associations for a range
ofchronicdiseasesincluding:type1diabetes;
13,14type 2
diabetes;
14–18 coronary artery disease;
14,19–21 breast
cancer;
22,23 colorectal cancer;
24–26 prostate cancer;
27,28
age-related macular degeneration
29–31 and Crohns
disease.
14,32 But, prior to these recent contributions,
genetic association studies were strikingly inconsis-
tent.
7–9,33–42 Although numerous scientific and techni-
cal issues were blamed,
10,33,35,37,40,43–47 perhaps the
most fundamental problem was a serious lack of
statistical power.
10,33,35,37,40,43–47 This raises important
questions: how large must stand-alone and nested
case–control studies really be if they are to power
contemporary gene discovery? And specifically, will
the current generation of ‘large’ initiatives,
14,48,49
http://www.genome.gov/17516722, http://www.p3gob
servatory.org, generate enough power to study the
joint effects of genes and environment?
50
These questions are crucial. Governments and
funding agencies worldwide are deciding whether,
and how much, to invest in population genomics.
Difficult strategic decisions, with imposing price
tags and substantial opportunity costs have to be
taken. In Europe, for example, national governments
must decide whether to adopt the European Union’s
regional road map for research infrastructures in ‘big
science’. This proposes development of a harmonized
pan-European network of biobanks. But, are pre-
existing projects, like UK Biobank,
48 the Wellcome
Trust case control consortium (WTCCC),
14 EPIC
(European prospective investigation into cancer and
nutrition)
51 and BioHealth Norway
52 already large
enough to service all foreseeable needs, or is further
investment required to facilitate larger pooled ana-
lyses and more powerful replication studies?
Rigorous power calculations are needed, but conven-
tional approaches disregard key elements of analytic
complexity, including the bioclinical complexity of
causal pathways leading to disease and the inferen-
tial complexity that arises from key aspects of study
design, conduct and analysis. For example, errors in
assessing disease status and aetiological determinants
are known to dramatically reduce statistical power if
the primary outcome is a quantitative disease-related
phenotype.
53 But, although their importance has been
emphasized,
54 they are typically ignored by conven-
tional power calculations for case–control studies.
This article describes and applies a simulation-based
approach to power calculation for case–control studies
in population genomics, generating a realistic power
profile across a range of meaningful bioclinical
scenarios. It also explores the incidence of common
chronic diseases in a typical population-based cohort
study recruiting middle-aged adults. Taken together,
these data provide a logical basis for deciding the
appropriate size of major new initiatives in population
genomics, including the construction of disease-based
and population-based biobanks and the pulling
together of consortia based on case series, population
controls, case–control projects and/or cohort studies.
Materials and methods
All simulations were carried out in the statistical
programming environment ‘R’.
55
The required size of case–control analyses
Simulation-based power calculation involves two
steps—simulation and analysis. Here, both steps
were based on logistic regression. All analyses in the
main paper utilize an unmatched case–control design
enrolling unrelated individuals with four controls
per case (alternative case: control ratios are consid-
ered in Supplementary materials, and Supplementary
Figure S1). Unless otherwise stated, genetic and
environmental determinants are all dichotomous
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Supplementary methods include: (i) full specification
of the mathematical models used (equations A–K);
(ii) an annotated version of the R code for the
primary simulation programme and (iii) discussion of
the key assumptions invoked in the analysis and the
effect of modifying them. Formal estimates of type 1
error were all nominal (Supplementary Table S1).
Genetic variants were modelled as having two
levels: ‘at risk’ and ‘not at risk’. This would apply,
for example, under a dominant genetic model
(Supplementary box S1): one detrimental allele puts
you ‘at risk’, but that risk is increased no further by a
second copy. Under such a model, 9.75% of the general
population would be ‘at risk’ if the minor allele
frequency (MAF) was 5%, and at-risk prevalences of
19, 51 and 75% would correspond to MAFs of 10, 30
and 50%, respectively. A dichotomous genetic variant
represents the setting of least power that is commonly
encountered and it was for this reason that it was used
as the default in the main paper. When it is
mathematically valid, more power and a smaller
sample size requirement, may be obtained if an
additive genetic model (in contrast to a dichotomous
model) is used. This model, which is used widely—
e.g.
14—is considered further in the discussion.
Interaction terms reflect departures from a multi-
plicative model—i.e. from additivity on the scale of
log odds—[Supplementary methods, equations (A–C)].
In simulation studies, where a gene–environment
interaction is of primary interest, the main effect ORs
(odds ratios) associated with the genetic and environ-
mental determinant is fixed at 1.5 while the magnitude
of the interaction term is varied: results are insensitive
to changing this fixed magnitude (Supplementary
Table S2).
Step 1 (simulation)
The parameters characterizing each scenario (a series of
simulations all using the same bioclinical parameters)
were set, and varied, under the following assumptions:
(i) Prevalence of the ‘at risk’ genotypic and envi-
ronmental determinants [0.0975 (MAF¼5%) or 0.51
(MAF¼30%), and 0.1 or 0.50, respectively]; (ii) ORs
associated with genotypic and environmental main
effects (1.10–3.0), and gene–environment interactions
(1.20–10.00); (iii) Sensitivity and specificity of disease
assessment appropriate to the particular disease
under consideration (e.g.
56, Supplementary box S2);
Supplementary materials and Supplementary Figure S2
explore the impact of changing sensitivity and specifi-
city; (iv) Controls assessed clinically in the same way as
cases (except in the real WTCCC data); (v) Errors in
classifying genotypes modelled as if arising primarily
from incomplete linkage disequilibrium (LD) between
an observed marker and a causative variant [R
2¼1.00
(no error), 0.80
57 or 0.50]; (vi) Lifestyle/environmental
exposure status determined by dichotomization of
an underlying quantitative variable measured with
error equivalent to a test–retest reliability of (a) 100%,
(b)90%,(c)70%,(d)50%or(e)30%;(vii)Heterogeneity
of underlying disease risk modelled using a random
effect
58 with a variance reflecting a 10-fold ratio in
baseline risk between individuals on ‘high’ (95%) and
‘low’ (5%) population centiles; Supplementary materi-
als and Supplementary Figure S3 investigate changing
the heterogeneity of risk; (viii) Disease prevalence
appropriate to the particular disease under considera-
tion
56; Supplementary materials and Supplementary
Figure S4 explore changing disease prevalence; (ix)
Statistical significance defined at 10
 7 for a genome
wide association (GWA) study and 10
 4 for a candidate
gene study or for gene–environment interactions
(Supplementary methods) and (x) No correction was
made for substructure in population ancestry.
14
Having set the required parameters, a dataset (D1)
was simulated (Supplementary methods, equations
A–F), containing cases and controls each associated
with a set of aetiological determinants (e.g. a gene
and an environmental determinant) distributed as
would be expected for a case–control study given the
particular bioclinical parameters specified.
Step 2 (analysis)
Dataset D1 was analysed using unconditional logistic
regression (Supplementary methods, equations G–J),
as if it were a real case–control study. This generated
estimates (and associatedstandard errors and P-values)
for the regression coefficients reflecting the genetic
and environmental main effects and, where incorpo-
rated, a gene–environment interaction. On the basis
of the pre-specified type 1 error, D1 was categorized
as either ‘significant’ or ‘non-significant’ for each of
the genetic, environmental and interaction effects.
Under each scenario, steps 1 and 2 were repeated
many times (51000), generating and analysing
datasets D2,D3,...,etc. The empirical statistical power
of the test for each effect was then estimated as the
proportion of the simulated datasets for which step 2
generated a ‘statistically significant’ result. Given the
estimated power of a study based on whatever
number of cases and controls had actually been
specified under the particular scenario being consid-
ered, the sample size for an equivalent study
(including the same ratio of controls to cases) that
would generate a power of 80% was estimated as
described in Supplementary methods (equation K). In
exploring the power profile across a range of ORs, the
required sample size for each OR was calculated,
tabulated and plotted (Figures 1 and 2).
This approach is very flexible and can easily be
extended by adding additional terms (Supplementary
methods).
The expected incidence of chronic disease
in population-based cohorts
The number of incident cases of selected chronic
diseases of public health relevance expected to
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cohort of 500000 individuals, recruited over 5 years,
with equal numbers enrolled in all 5 year age
bands between 40 and 69 years at entry (Figure 3).
This simulated cohort corresponds closely to the
design of UK Biobank
48 and provides important
parallels to other cohorts worldwide (www.p3gobser
vatory.org). Each recruit was simulated in ‘R’ and his/
her subsequent life-course was simulated taking
appropriate account of the chance occurrence of
disease, migrations, loss to follow-up and deaths
(sources for the vital statistics are detailed in
Supplementary Table S3). Adjustment was also
made for the ‘healthy cohort effect’, whereby subjects
recruited to cohort studies typically experience lower
rates of morbidity than the general population.
Results
Figure 1 presents the sample size needed for 80%
power to detect (at P<0.0001) the main effect of a
Figure 1 A genetic main effect, in a candidate gene study.
The number of cases required to detect ORs from 1.1 to
3.0 for a genetic main effect with a power of 80% (at
P<0.0001—assuming a vague candidate gene) in a study
with four controls per case. Assumptions (see Materials and
methods section for details): (i) population genotypic
prevalence¼9.75% [dashed lines] or 51% [solid lines],
corresponding to dominant SNP effects with MAFs (minor
allele frequencies) of 5 and 30%, respectively; (ii) genotypic
‘error’ corresponding to: R
2¼1.0, 0.8 or 0.5; (iii) case-status
determined with sensitivity 89.1% and specificity 97.4%: as
for a study of diabetes diagnosed by a composite test (GP
diagnosis or HbA1C 52 SD above the population mean
56);
(iv) controls phenotypically assessed in the same way as
cases; (v) incorporation of heterogeneity in the baseline risk
of disease arising from unmeasured determinants, corre-
sponding in magnitude to a 10-fold risk ratio between
individuals on the high (95%) and low (5%) centiles of
population risk
Figure 2 (A) An uncommon interaction. The number of
cases required to detect ORs from 1.2 to 10.0 for a gene–
environment interaction with a power of 80% (at P<10
 4)
in a study with four controls per case. Assumptions (see
Materials and methods section for details): (i) population
genotypic prevalence¼9.75%, corresponding to a dominant
SNP effect with a MAF of 5%; (ii) population prevalence of
binary environmental determinant¼20%; (iii) genotypic
‘error’ corresponding to r
2¼0.8; (iv) environmental error
corresponding to dichotomization of an underlying normally
distributed latent quantitative variable measured with a
reliability of 100, 90, 70, 50 or 30%; (v) case–control status
determined with sensitivity 89.1% and specificity 97.4%: as
for a study of diabetes diagnosed by a composite test (GP
diagnosis or HbA1C 52 SD above the population mean
56);
(vi) controls phenotypically assessed in the same way as
cases; (vii) incorporation of heterogeneity in the baseline
risk of disease arising from unmeasured determinants,
corresponding in magnitude to a 10-fold risk ratio between
individuals on the high (95%) and low (5%) centiles of
population risk. The prevalences of the ‘at risk’ genotype
and the ‘at risk’ environmental determinant imply a
prevalence of  2% for the doubly ‘at risk’ interaction.
(B) A common interaction. As (A), but assuming: population
genotypic prevalence¼51% (corresponding to MAF¼30%)
and prevalence of the environmental determinant¼50%,
implying prevalence of the doubly ‘at risk’ interaction  25%
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candidate gene, using an unmatched case–control
design enrolling four controls per case. As detailed in
the Materials and methods section, and summarized
in the figure legend, these calculations all incorporate
cardinal elements of realistic analytic complexity.
Table 1 details the multiplicative factor by which the
sample sizes in the figure should be scaled if a P-value
other than P<0.0001 is to be used or if one requires a
power of 50 or 90% rather than 80%.
Figures 2A and B present sample size requirements for
studies of gene–environment interaction (see Materials
and Methods section, with details in Supplementary
methods). Phenotypic and genotypic characteristics
are detailed in the figure legend. Figure 2A considers
an uncommon interaction where ‘doubly-at-risk’
individuals (i.e. subjects exposed to the at-risk level of
both the genetic and the lifestyle determinant) repre-
sent  2% of the general population. Figure 2B
addresses a common interaction with  25% of individ-
uals being doubly-at-risk. Each figure details the
sample size profile for a range of errors in assessing
the environmental factor (see Materials and methods
section). As a benchmark, Table 2 presents biocli-
nical exemplars that are typically measured with a
corresponding reliability. Significance testing is at
P<0.0001: i.e. it is assumed that research involving
the joint effects of genes and environment will focus
on specific interactions with at least some vague basis
for candidature. If a more rigorous threshold is
required, the sample size multipliers in Table 1 may
be used.
In light of the daunting sample size requirements
implied by Figures 1 and 2, Figure 3 demonstrates
that a cohort of 500000 middle-aged recruits may be
expected to generate 10000 incident cases of very
common conditions (e.g. diabetes and coronary artery
disease) within 7–8 years, and 20000 cases within
15 years. But even for the commonest cancers it will
take  20 years or more to generate 10000 cases and
440 years to generate 20000 cases. Such targets will
never be attained for rarer conditions. However,
population-based cohort studies also recruit prevalent
cases of chronic disease (Supplementary Table S4)
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Figure 3 Time to achieve required numbers of cases.
The expected rate of generation of incident cases of 16
common complex diseases (MI¼myocardial infarction;
COPD¼chronic obstructive pulmonary disease) in a cohort
of 500000 men and women recruited over 5 years, aged
40–69 years at baseline, assuming rates of mortality and
morbidity as in the UK and that drop-out mirrors that of
the British 1958 birth cohort and with adjustment for the
‘healthy cohort’ effect (for full details see
68)
Table 1 The multiplicative change in required sample size, for a statistical power of 50, 80 or 90% using different levels of
statistical significance, relative to the sample size indicated by Figures 1 and 2 (i.e. when P<0.0001 and power¼80%)
P-value defining ‘statistical significance’ Sample size multiplier for specified power
Power¼50% Power¼80% Power¼90%
Significance thresholds conventionally used in medical statistics
P<0.05 0.172 0.350 0.469
P<0.01 0.296 0.522 0.664
Significance thresholds widely used in candidate gene studies
P<0.005 0.352 0.594 0.746
P<0.001 0.484 0.762 0.933
P<0.0005 0.541 0.834 1.013
P<0.0001 0.676 as in figures 1.195
Significance thresholds widely used in GWA studies
P<5 10
 7 1.128 1.538 1.777
P<10
 7 1.267 1.699 1.950
P<5 10
 8 1.327 1.768 2.024
P<10
 8 1.467 1.929 2.196
Sample size multipliers more than 1 indicate that the required sample size is larger than implied by the figures, values less than 1
that it is smaller.
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supplement statistical power.
Discussion
‘Big’ bioscience is critically poised. It is now known that
genetic associations with complex diseases can reliably
be detected and replicated if sample sizes are large
enough. This will fuel international investment in
biobanking. But, how far should that investment go?
It is essential to close the ‘reality-gap’ that currently
exists between the sample sizes really required to
detect determinants of scientific interest that have
plausible bioclinical effects, and the sample sizes that
are typically used when studies are being designed.
Extensive theoretical work has been undertaken to
explore statistical power and sample size in human
genomics. This includes studies of the effect of geno-
type misclassification on power,
59–62 and of strategies
for power optimization for genetic main effects
63–64
and for gene–gene
65 and gene–environment interac-
tions.
66 Furthermore, the effect of measurement error
in both outcomes and exposures on statistical power
of gene–environment interaction studies has been
explored thoroughly for quantitative traits.
53 But,
previous work on the power of case–control analyses
(i.e. binary traits) has not addressed the impact of
realistic assessment errors in both exposures and
outcomes and the impact of unmeasured aetiological
determinants. The important original contributions of
the current article are 3-fold, therefore: (i) to extend
the classes of analytic complexity addressed in a
straightforward simulation-based power calculation
engine; (ii) to use this calculator to undertake realistic
sample size calculations for a class of analyses (case–
control analyses with unavoidable assessment errors
in both exposures and outcomes) that will be utilized
widely over the next few decades—analyses in this
class are the least powerful that are likely to be
applied commonly, and the resultant calculations,
therefore, provide a valuable guide to study design in
the many large-scale biobanks that are currently
being conceived and launched; (iii) to alert readers,
particularly those setting up new biobanks, to a
web-based implementation—ESPRESSO (Estimating
Sample-size and Power in R by Exploring Simulated
Study Outcomes)—of the power calculator used in
this article and to provide detailed information
(in Supplementary methods) about the mathematical
models on which it is based.
Studies enrolling several hundred subjects are
commonplace in human genome epidemiology. But,
even conventional power calculations
67 indicate that
400 cases and 400 controls provide <1% power to
detect (at P<0.0001) an OR of 1.4 for a binary
‘at risk’ genetic variant with a general population
frequency of 0.0975 (e.g. a dominant risk-determining
allele with MAF¼0.05). There can be no doubt that a
study involving several hundred cases and controls
demands hard work and is large by historical
comparison; nevertheless, the reality is that to gen-
erate a power of 80%, such a study would actually
require 4000 cases and 4000 controls.
But even these figures substantially understate the
challenge that really faces us. Conventional power
calculations ignore many aspects of analytic complex-
ity. Using ESPRESSO, the R-based
55 simulation-
based power calculator
68 jointly developed by P
3G,
PHOEBE and UK Biobank (www.p3gobservatory.org/
powercalculator.htm), such complexities can be taken
into proper account. Using this approach to mimic the
conventional power calculation (above)—i.e. assum-
ing disease and genotype to be assessed without error
and no heterogeneity in disease risk—confirms a
requirement for approximately 4000 cases and 4000
controls. But the sensitivity and specificity of the
diagnostic test ought to be taken into proper account:
e.g. 0.891 and 0.974, respectively, for a published
screening test for type 2 diabetes based on glycosy-
lated haemoglobin
56 (see Supplementary box 2).
Genotyping error must also be considered. It may,
for example, be reasonable to assume that this
corresponds to incomplete LD with an R
2 of 0.8.
57
Finally, heterogeneity in disease risk might be
reflected in an assumed 10-fold ratio in the risk
between subjects on high (95%) and low (5%) centiles
of population risk. Having built in these assumptions,
the required sample size more than doubles to 8500
cases and 8500 controls.
It might be argued that substantial power could be
gained if amultiplicative model based on additive allelic
effects [Supplementary methods, equations (H and I)],
as in WTCCC,
14 were used instead of a binary genetic
model (Supplementary box S1). Statistical power will
be increased if there is a systematic gradation in the
strength of association across the three genotypes
defined by two alleles. This may reflect biological
Table 2 Formal estimates of test–retest reliability for a
number of exemplar lifestyle/environmental determinants
that are widely studied
Reliability of
measurement
Lifestyle/environmental
factor
50.95 Body mass index (BMI)
calculated from measured height
and weight in various studies
76
 0.9 Measured hip or waist
circumference
76,77
 0.7 Blood pressure measurement in
the Intersalt Study
78
 0.5 Many nutritional components in
a dietary recall study, mean
of four 24h assessments
79
 0.3 Many nutritional components in
a dietary recall study, a single
24h assessment
79
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incomplete LD when working with a linked marker
rather than a causative variant. But (Supplementary
Figure S5), the reduction in required sample size
(typically, 5–50%) is only substantial for SNPs with a
common minor allele. This is because when the minor
allele is rare, subjects homozygous for the minor allele
will be very rare and the genetic determinant will
effectively act as if it were a binary exposure. But,
power limitation is less of a problem for SNPs with a
common minor allele and so the impact of moving to
a valid multiplicative genetic model is less dramatic
than might otherwise be assumed.
One of the landmark genomic studies of 2007 was
the WTCCC that reported robust ‘hits’ in seven of
eight complex diseases in its main experiment.
14 But
the basic design—involving 2000 cases and 3000
controls for each disease—seems, at first sight, to be
at the lower limit of required sample size as implied
by our calculations (Figure 1). Therefore, it is tempt-
ing to conclude either that the WTCCC was lucky or
that our calculations are overly conservative. But, the
main experiment of WTCCC had a number of design
features that contrast with the assumptions of the
primary power calculations reported in our article.
14
The most relevant of these are: (i) use of a model
invoking an additive genetic effect rather than a
binary ‘at-risk’ genotype; (ii) cases rigorously pheno-
typed so that few, if any, non-diseased subjects will
have appeared as cases; (iii) a P-value threshold of
5 10
 7; (iv) a case:control ratio of 2:3; (v) no
phenotyping of controls so diseased subjects will have
contaminated the controls to an extent determined
solely by general population prevalence. On the basis
of simulations that invoke all of these assumptions,
Supplementary Figure S6 presents the precise equiva-
lent to Figure 1, but uses the design parameters of the
WTCCC. On the basis of their own simulation-based
power calculations (incorporating errors consequent
upon incomplete LD),
14 the design team of the
WTCCC estimated that its power would be ‘43% for
alleles with a relative risk of 1.3, increasing to 80% for
a relative risk of 1.5’.
14 These power calculations were
based on averaging across all MAFs40.05,
14 and the
design should, therefore, be underpowered for SNPs
with an uncommon minor allele and to have more
power than required for common SNPs.
14 Our
methods (Supplementary Figure S6) concur that for
SNPs with a MAF in the range 0.2–0.5, the WTCCC
design was well powered to detect heterozygote ORs
14 of
1.3 or greater and that even ORs as low as 1.2 should
have been detected with a non-negligible probability
(power  9%). On the other hand, the power to detect
rarer SNPs (MAF¼0.05–0.1) with ORs <1.5 should
have been low. Without knowing which SNPs are
truly associated with which complex disease, or how
strong those associations might be, it is impossible to
use the empirical evidence to precisely quantify how
accurately our approach predicts the power of the
WTCCC. But, the predicted power profile is certainly
consistent with the results reported in Table 3 of the
WTCCC paper.
14 Three of the 19 SNPs they identified
as having a ‘significant heterozygous OR’, had a MAF
between 0.05 and 0.1 and these all had OR41.5. In
contrast, 13 had a MAF between 0.2 and 0.5 and of
these, four exhibited an OR<1.3 (1.19–1.29), five an
OR between 1.3 and 1.5 and four an OR41.5. SNPs
with a rarer minor allele are typically most common,
57
and if power was not a substantial issue, one would
have expected more ‘hits’ to arise in rare SNPs. It is
true that the observed ORs would have been subject
to the ‘winner’s curse’,
69 but this does not detract
from the consistency of the overall pattern that was
found. As a second test of its validity, the ESPRESSO
model was then used to estimate the power of the
WTCCC to reconfirm the effect of 12 (non-HLA) loci
that had been ‘previously robustly replicated’.
14 On
the basis of the published bioclinical characteristics of
these 12 variants (Supplementary Table S5), our
simulations predicted a 24% probability that all 12
would replicate and probabilities of 44, 26 and 6%,
respectively, that 11, 10 or 49 would replicate. These
predictions are closely consistent with the published
WTCCC analysis in which 10 of the 12 actually
replicated.
14 Of course, these analyses provide no
more than a rudimentary check of the calibration
of our approach, nevertheless, it is encouraging that
the predictions appear sensible and it would, there-
fore, seem reasonable to apply the methods to new
problems, including those involving environmental as
well as genetic determinants.
The fact that our power estimates appear consistent
with those of the WTCCC team itself suggests that
any additional elements of analytic complexity that
were addressed by our methods had a limited impact
on required sample size in this particular setting.
Therefore, we explored the relative contribution to
increased sample size requirement that was consequent
upon those specific elements of our model that are not
included in a conventional power calculation. Across an
arbitrary, but not atypical, set of models incorporating a
gene–environment interaction (see Supplementary
materials, and Supplementary Table S6), it was found
that it is a realistic level of error in assessing the
environmental determinant that was most influential
in inflating the required sample size. But, the WTCCC
analysis focused solely on genetic main effects and so
this was irrelevant. Furthermore, all cases in WTCCC
were carefully phenotyped. Specificity was, therefore,
close to 100% and very few, if any, healthy subjects
would have appeared as cases (Supplementary materi-
als and Supplementary Figures S2a and S2b). Finally,
the sophisticated power calculations undertaken by
WTCCC took appropriate account of error arising from
incomplete LD, and so the only additional factor that
did come into play in the WTCCC was heterogeneity
in underlying disease risk—but, on its own, this has
little impact (Supplementary Table S6).
EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 269 EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 269Can biobanks ever be large enough? Although our
methods are in accord with the power calculations
undertaken by the WTCCC and suggest that it was
appropriately powered to detect the effects that it set
out to study, larger—sometimes much larger—sample
sizes will be required (Figures 1 and 2) to reliably
detect: (i) ORs at the lower end of the plausible
range; (ii) SNP effects associated with rarer minor
alleles; (iii) genotypic effects that are binary rather
than multiplicative in nature; (iv) gene–environment
(or, gene–gene) interactions or (v) aetiological effects
in case series subject to less exhaustive phenotyping.
If bioscience aims to rigorously investigate such
effects, it will be necessary to design studies enrolling
not thousands, but tens of thousands of cases. But,
studies of such a size should not be contemplated
unless relative risks 41.5 are really worth investigat-
ing. A central aim of modern bioscience is to under-
stand the causal mechanisms underlying complex
disease
49,70 and each quantum of new knowledge has
the potential to provide an important insight that may
have a dramatic impact on disease prevention or
management. This implies that scientific interest may
logically focus on any causal association that can
convincingly be identified and replicated—it need not
be ‘strong’ by any statistical or epidemiological cri-
terion. The fundamental need, therefore, is for
research platforms to support analyses powered to
detect plausible aetiological effects. But, what does this
mean? The majority of genetic effects on chronic
diseases that have so far been identified and
replicated are characterized
8,9,13–32 by allelic or geno-
typic relative risks of 1.5 or less—many in the range
1.1–1.3. Effect sizes may be greater for causal variants
than for markers in LD, but it would be unwise to
assume that the gain will necessarily be substantial.
Although the search for ‘low hanging fruit’ must
continue, therefore, we agree with Easton et al.
22 that
much of the future harvest will be rather higher up
the tree. But, even if they are of scientific interest, can
ORs 41.5 reliably be detected by any observational
study? In 1995, Taubes argued that: ‘[observational
epidemiological studies]...are so plagued with biases,
uncertainties, and methodological weaknesses that
they may be inherently incapable of accurately dis-
cerning...weak associations’.
71 Fortunately, several of
the central arguments underlying this bleak assessment
do not hold in human genome epidemiology. Random-
ization at gamete formation renders simple phenotype–
genotype associations robust to life style confounding
and to uncertainty in the direction of causality—in
other words, enhanced inferential rigour is a direct, but
wholly fortuitous, consequence of what is often called
Mendelian randomization.
70,72–74 At the same time, the
increasing accuracy and precision of measurements in
genome epidemiology
14,53,54 mean that—in the absence
of intractable confounding and reverse causality—
sufficient statistical power can realistically be accrued
to draw meaningful inferences for small effect sizes.
Despite important caveats,
70,73,75 therefore, small
effects reflecting the direct impact of genetic determi-
nants (main effects and gene–gene interactions) or the
differential impact of genetic variants in diverse
environmental backgrounds (gene–environment inter-
actions) are more robust than their counterparts in
traditional environmental epidemiology.
Finally, we note that the primary simulations that
underpin our conclusions are all based on a case:
control ratio of 1:4, while a 1:1 ratio was adopted
in considering the ‘conventional’ power calculations
(see above). Furthermore, most of the case–control
studies that we reference (including the WTCCC) are
based on ratios that are much closer to unity.
13–32 But
this presentation was deliberate. Given access to a
fixed number of cases and an unrestricted number of
well-characterized controls, substantial additional
power can be obtained using a design based on four
or more controls per case (Supplementary Figure S1).
In the future, the existence of massive population-
based biobanks such as UK Biobank
48 and extensive
sets of nationally representative controls (e.g. as in
WTCCC
14) will mean that designs based on multiple
controls will be highly cost effective and will be
widely used. It would, therefore, have been inap-
propriate to present power calculations based primar-
ily on the 1:1 design as this would have increased the
estimated sample size requirement, thereby strength-
ening our main message in a manner that could have
been seen as misleading. On the other hand, in
exploring the implications of conventional power
calculations (see above), most contemporary work is
based on designs with approximately equal number of
cases and controls and it was, therefore, felt to be
more intuitive for readers to focus on designs of this
nature. For the sake of completeness, Supplementary
Figures S7, S8a and S8b replicate Figures 1, 2A and B
but use equal numbers of cases and controls.
To finish, we note that the basic conclusions we have
reached are stark and may appear disheartening. But,
pessimism is unwarranted. Disentangling the causal
architecture of chronic diseases will be neither cheap
nor easy and it would be unwise to assume otherwise.
But it has the potential to return investment many-
fold with future improvements in promoting health
and combating disease. Therefore, it is encouraging that
several international case–control consortia have
already managed to amass sample sizes of
the magnitude that is realistically required.
16,19,22,26
Furthermore, the largest contemporary cohort-based
initiatives
48,49,51,52 will generate enough cases to study
the commonest diseases in their own right (Figure 3).
To take things further, three complementary strategies
will markedly enhance the capacity to study plausible
relative risks right across the spectrum of complex
diseases: (i) improve the accuracy and precision of
measurements and assessments;
14,53,54 (ii) increase the
size of individual studies and biobanks
8 and (iii) har-
monize protocols for information collection, processing
270 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYand sharing
10,46–49,70 (http://www.p3g.org). Taken tog-
ether, these actions will provide for a powerful global
research platform to drive forward our understanding
of the causal architecture of the common chronic
diseases. But, such a platform will be of little value
unless power calculations are both accurate and realistic.
It is our hope that this article and access to ESPRESSO
will be viewed as providing valuable guidance to those
setting up individual biobanks and designing the case–
control analyses to be based upon them.
Supplementary data
Supplementary data are available on the P3G
Observatory http://www.p3gobservatory.org.
Acknowledgements
We gratefully acknowledge the support of the steering
committee of UK Biobank in encouraging and
discussing the implications of this research. Initial
power calculations were funded by UK Biobank from
its joint funders: Wellcome Trust, Medical Research
Council, Department of Health, Scottish Executive
and Northwest Regional Development Agency.
This work was also supported as a central element
of the research programmes of P
3G (the Public
Population Project in Genomics) funded by Genome
Canada and Genome Quebec, and PHOEBE
(Promoting Harmonization of Epidemiological
Biobanks in Europe) funded by the European Union
under the Framework 6 program. A.L.H. is a
Wellcome Trust Intermediate Clinical Fellow (grant
number 075883). J.L. is a Canada Research Chair in
Human Genome Epidemiology. The programme of
methods research in genetic epidemiology in Leicester
is funded in part by MRC Cooperative Grant
G9806740. We wish to thank those who kindly
provided us with advice and data: Gabriele Nagel,
Sabine Rohrman, Bertrand Hemon, Paolo Vineis
[European Prospective Investigation of Cancer and
Nutrition (EPIC)]; Peter Rothwell (Stroke Prevention
Research Unit, Radcliffe Infirmary, Oxford); Joan
Soriano, GlaxoSmithKline (for estimates of UK
COPD incidence) and the UK Small Area Health
Statistics Unit, Imperial College London.
Conflict of interest: None declared.
References
1 World Health Organization (WHO). Diet, Nutrition and the
Prevention of Chronic Diseases. The Aethiology of these Diseases.
Geneva: Joint WHO/FAO Expert Consultation, 2005.
2 O’Rahilly S, Wareham NJ. Genetic variants and common
diseases–better late than never. N Engl J Med 2006;
355:306–8.
3 Lander ES. The new genomics: global views of biology.
Science 1996;274:536–39.
4 Cargill M, Daley GQ. Mining for SNPs: putting the
common variants–common disease hypothesis to the test.
Pharmacogenomics 2000;1:27–37.
5 Reich DE, Lander ES. On the allelic spectrum of human
disease. Trends Genet 2001;17:502–10.
6 Pritchard JK, Cox NJ. The allelic architecture of human
disease genes: common disease-common variant...or
not? Hum Mol Genet 2002;11:2417–23.
EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 271
KEY MESSAGES
  Biobanking is very expensive and the effect sizes to be investigated are often very small—accurate
sample size estimation is vital, therefore.
  Conventional power calculations for case–control comparisons ignore key aspects of analytic complexity
and can substantially understate sample size requirements—often by a factor of two or more.
  Power profiles for stand-alone and nested case–control studies are presented that are based on a
simulation-based approach to calculation that takes robust account of analytic complexity (including
several forms of assessment error) and has been implemented as the web-based utility ESPRESSO
(http://www.p3gobservatory.org/powercalculator.htm).
  Taking appropriate account of realistic constraints on statistical power, any research infrastructure
aimed at providing a robust platform for exploring genomic association will typically require several
thousands of cases to study main effects and several tens of thousands of cases to properly support the
investigation of gene–gene or gene–environment interaction.
  In order to enhance scientific return from the massive international investment in biobanking, power
calculations must be both accurate and realistic and individual biobanks must be designed so as to
enhance the quality of the data and samples that are collected, and harmonized to facilitate data
sharing and pooled analysis.
EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 2717 Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A
comprehensive review of genetic association studies.
Genet Med 2002;4:45–61.
8 Lohmueller KE, Pearce CL, Pike M, Lander ES,
Hirschhorn JN.Meta-analysis ofgenetic association studies
supports a contribution of common variants to suscept-
ibility to common disease. Nat Genet 2003;33:177–82.
9 Hattersley AT, McCarthy MI. What makes a good genetic
association study? Lancet 2005;366:1315–23.
10 Khoury MJ, Little J, Gwinn M, Ioannidis JP. On the
synthesis and interpretation of consistent but weak
gene-disease associations in the era of genome-wide
association studies. Int J Epidemiol 2007;36:439–45.
11 Risch N, Merikangas K. The future of genetic studies of
complex human diseases. Science 1996;273:1516–17.
12 Terwilliger JD, Weiss KM. Confounding, ascertainment
bias, and the blind quest for a genetic ‘fountain of youth’.
Ann Med 2003;35:532–44.
13 Todd JA, Walker NM, Cooper JD et al. Robust associations
of four new chromosome regions from genome-wide
analyses of type 1 diabetes. Nat Genet 2007;39:857–64.
14 Wellcome_Trust_Case_Control_Consortium. Genome-wide
association study of 14,000 cases of seven common diseases
and 3,000 shared controls. Nature 2007;447:661–78.
15 Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of
transcription factor 7-like 2 (TCF7L2) gene confers risk of
type 2 diabetes. Nat Genet 2006;38:320–23.
16 Zeggini E, Weedon MN, Lindgren CM et al. Replication of
genome-wide sssociation signals in U.K. samples reveals
risk loci for type 2 diabetes. Science 2007;316:1336–39.
17 Saxena R, Voight BF, Lyssenko V et al. Genome-wide
association analysis identifies loci for type 2 diabetes and
triglyceride levels. Science 2007;316:1331–36.
18 Scott LJ, Mohlke KL, Bonnycastle LL et al. A genome-
wide association study of type 2 diabetes in Finns detects
multiple susceptibility variants. Science 2007;316:1341–45.
19 Samani NJ, Erdmann J, Hall AS, Hengstenberg C,
Mangino M, Mayer B. Genome-wide association analysis
of coronary artery disease. N Engl J Med 2007;357:443–53.
20 Helgadottir A, Thorleifsson G, Manolescu A et al.A
common variant on chromosome 9p21 affects the risk of
myocardial infarction. Science 2007;316:1491–93.
21 McPherson R, Pertsemlidis A, Kavaslar N et al. A common
allele on chromosome 9 associated with coronary heart
disease. Science 2007;316:1488–91.
22 Easton DF, Pooley KA, Dunning AM, Pharoah PDP,
Thompson D, Ballinger DG. Genome-wide association
study identifies novel breast cancer susceptibility loci.
Nature 2007;447:1087–93.
23 Stacey SN, Manolescu A, Sulem P et al. Common variants
on chromosomes 2q35 and 16q12 confer susceptibility to
estrogen receptor-positive breast cancer. Nat Genet
2007;39:865–69.
24 Haiman CA, Le Marchand L, Yamamato J, Stram DO,
Sheng X, Kolonel LN. A common genetic risk factor for
colorectal and prostate cancer. Nat Genet 2007;39:954–56.
25 Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P,
Kemp Z, Spain S. A genome-wide association scan of tag
SNPs identifies a susceptibility variant for colorectal
cancer at 8q24.21. Nat Genet 2007;39:984–88.
26 Zanke BW, Greenwood CM, Rangrej J, Kustra R,
Tenesa A, Farrington SM. Genome-wide association
scan identifies a colorectal cancer susceptibility locus on
chromosome 8q24. Nat Genet 2007;39:989–94.
27 Gudmundsson J, Sulem P, Steinthorsdottir V,
Bergthorsson JT, Thorleifsson G, Manolescu A. Two
variants on chromosome 17 confer prostate cancer risk,
and the one in TCF2 protects against type 2 diabetes.
Nat Genet 2007;39:977–83.
28 Gudmundsson J, Sulem P, Manolescu A et al. Genome-
wide association study identifies a second prostate cancer
susceptibility variant at 8q24. Nat Genet 2007;39:631–37.
29 Klein RJ, Zeiss C, Chew EY et al. Complement factor H
polymorphism in age-related macular degeneration.
Science 2005;308:385–89.
30 Haines JL, Hauser MA, Schmidt S et al. Complement
factor H variant increases the risk of age-related macular
degeneration. Science 2005;308:419–21.
31 Edwards AO, Ritter R 3rd, Abel KJ, Manning A,
Panhuysen C, Farrer LA. Complement factor H poly-
morphism and age-related macular degeneration. Science
2005;308:421–24.
32 Rioux JD, Xavier RJ, Taylor KD et al. Genome-wide
association study identifies new susceptibility loci for
Crohn disease and implicates autophagy in disease
pathogenesis. Nat Genet 2007;39:596–604.
33 Ioannidis JP, Ntzani EE, Trikalinos TA. Contopoulos-
Ioannidis DG. Replication validity of genetic association
studies. Nat Genet 2001;29:306–9.
34 Tabor HK, Risch NJ, Myers RM. Opinion: candidate-gene
approaches for studying complex genetic traits: practical
considerations. Nat Rev Genet 2002;3:391–97.
35 Weiss KM, Terwilliger JD. How many diseases does it
take to map a gene with SNPs? Nat Genet 2000;26:151–57.
36 Goldstein DB, Ahmadi KR, Weale ME, Wood NW.
Genome scans and candidate gene approaches in the
study of common diseases and variable drug responses.
Trends Genet 2003;19:615–22.
37 Cardon LR, Bell JI. Association study designs for complex
diseases. Nat Rev Genet 2001;2:91–99.
38 Terwilliger JD, Goring HH. Gene mapping in the 20th and
21st centuries: statistical methods, data analysis, and
experimental design. Hum Biol 2000;72:63–132.
39 Palmer LJ, Cardon LR. Shaking the tree: mapping
complex disease genes with linkage disequilibrium.
Lancet 2005;366:1223–34.
40 Buchanan AV, Weiss KM, Fullerton SM. Dissecting
complex disease: the quest for the Philosopher’s Stone?
Int J Epidemiol 2006;35:562–71.
41 Moonesinghe R, Khoury MJ, Janssens AC. Most pub-
lished research findings are false-but a little replication
goes a long way. PLoS Med 2007;4:e28.
42 Chanock SJ, Manolio T, Boehnke M et al. Replicating
genotype-phenotype associations. Nature 2007;447:
655–60.
43 Risch NJ. Searching for genetic determinants in the new
millennium. Nature 2000;405:847–56.
44 Little J, Khoury MJ, Bradley L et al. The human genome
project is complete. How do we develop a handle for the
pump? Am J Epidemiol 2003;157:667–73.
45 Ioannidis JP, Gwinn M, Little J et al. A road map for
efficient and reliable human genome epidemiology. Nat
Genet 2006;38:3–5.
272 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY46 Khoury MJ, Millikan R, Little J, Gwinn M. The
emergence of epidemiology in the genomics age. Int J
Epidemiol 2004;33:936–44.
47 Little J, Bradley L, Bray MS et al. Reporting, appraising,
and integrating data on genotype prevalence and gene-
disease associations. Am J Epidemiol 2002;156:300–10.
48 Collins R and UK Biobank Steering Committee. UK
Biobank: Protocol for a Large-scale Prospective Epidemiological
Resource. Manchester: UK Biobank Coordinating
Centre, 2007.
49 Burton P, Fortier I, Deschenes M, Hansell A, Palmer L.
Biobanks and biobank harmonization. In: Davey SG,
Burton P, Palmer L (eds). An Introduction to Genetic
Epidemiology. Bristol: Policy Press (In press).
50 Hunter DJ. Gene-environment interactions in human
diseases. Nat Rev Genet 2005;6:287–98.
51 Weikert S, Boeing H, Pischon T et al. Fruits and
vegetables and renal cell carcinoma: findings from the
European prospective investigation into cancer and
nutrition (EPIC). Int J Cancer 2006;118:3133–39.
52 Husebekk A, Iversen O-J, Langmark F, Laerum OD,
Ottersen OP, Stoltenberg C. Biobanks for Health - Report and
Recommendations from an EU workshop. Oslo: Technical
report to EU Commission, 2003.
53 Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The
detection of gene-environment interaction for continuous
traits: should we deal with measurement error by bigger
studies or better measurement? Int J Epidemiol 2003;
32:51–57.
54 Schwartz D, Collins F. Medicine: environmental biology
and human disease. Science 2007;316:695–96.
55 R Development Core Team. R: A Language and
Environment for Statistical Computing. Vienna, Austria:
R Foundation for Statistical Computing, 2008.
56 Rohlfing CL, Little RR, Wiedmeyer HM et al. Use of GHb
(HbA1c) in screening for undiagnosed diabetes in the
U.S. population. Diabetes Care 2000;23:187–91.
57 Barrett JC, Cardon LR. Evaluating coverage of genome-
wide association studies. Nat Genet 2006;38:659–62.
58 Burton P, Gurrin L, Sly P. Extending the simple
linear regression model to account for correlated
responses: an introduction to generalized estimating
equations and multi-level mixed modelling. Stat Med
1998;17:1261–91.
59 de Bakker PI, Burtt NP, Graham RR et al. Transferability
of tag SNPs in genetic association studies in multiple
populations. Nat Genet 2006;38:1298–303.
60 Jorgenson E, Witte JS. A gene-centric approach to
genome-wide association studies. Nat Rev Genet
2006;7:885–91.
61 Gordon D, Finch SJ, Nothnagel M, Ott J. Power
and sample size calculations for case-control genetic
association tests when errors are present: application
to single nucleotide polymorphisms. Hum Hered 2002;
54:22–33.
62 Gordon D, Finch SJ. Factors affecting statistical power in
the detection of genetic association. J Clin Invest
2005;115:1408–18.
63 Gordon D, Leal SM, Heath SC, Ott J. An analytic solution
to single nucleotide polymorphism error-detection rates
in nuclear families: implications for study design.
Pac Symp Biocomput 2000;5:660–71.
64 Gordon D, Yang Y, Haynes C, Finch SJ, Mendell NR,
Brown AM. Increasing power for tests of genetic
association in the presence of phenotype and/or genotype
error by use of double-sampling. Stat Appl Genet Mol Biol
2004;3:26.
65 Marchini J, Donnelly P, Cardon LR. Genome-wide
strategies for detecting multiple loci that influence
complex diseases. Nat Genet 2005;37:413–17.
66 Bermejo JL, Hemminki K. Gene-environment studies:
any advantage over environmental studies? Carcinogenesis
2007;28:1526–32.
67 Armitage P, Berry G. Statistical Methods in Medical Research.
3rd edn. Oxford: Blackwell Scientific Publications, 1994.
68 Burton PR, Hansell A. UK Biobank: The Expected Distribution
of Incident and Prevalent Cases of Chronic Disease and the
Statistical Power of Nested Casecontrol Studies. Manchester,
UK: UK Biobank Technical Reports, 2005.
69 Iles MM. What can genome-wide association studies tell
us about the genetics of common disease? PLoS Genetics
2008;4:e33.
70 Davey Smith G, Ebrahim S, Lewis S, Hansell AL,
Palmer LJ, Burton PR. Genetic epidemiology and public
health: hope, hype, and future prospects. Lancet 2005;
366:1484–98.
71 Taubes G. Epidemiology faces its limits. Science 1995;
269:164–69.
72 Clayton D, McKeigue PM. Epidemiological methods for
studying genes and environmental factors in complex
diseases. Lancet 2001;358:1356–60.
73 Davey Smith G, Ebrahim S. ‘Mendelian randomization’:
can genetic epidemiology contribute to understanding
environmental determinants of disease? Int J Epidemiol
2003;32:1–22.
74 Tobin MD, Minelli C, Burton PR, Thompson JR.
Commentary: development of Mendelian randomization:
from hypothesis test to ‘Mendelian deconfounding’. Int J
Epidemiol 2004;33:26–29.
75 Didelez V, Sheehan N. Mendelian randomization as an
instrumental variable approach to causal inference. Stat
Methods Med Res 2007;16:309–30.
76 Klipstein-Grobusch K, Georg T, Boeing H. Interviewer
variability in anthropometric measurements and esti-
mates of body composition. Int J Epidemiol 1997;26
(Suppl 1):S174–80.
77 Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB,
Willett WC. Validity of self-reported waist and hip
circumferences in men and women. Epidemiology
1990;1:466–73.
78 Dyer AR, Shipley M, Elliott P, for the Intersalt
Cooperative Research Group. Urinary electrolyte excretion
in 24 hours and blood pressure in the INTERSALT
study: I. Estimates of Reliability. Am J Epidemiol
1994;139:927–39.
79 Grandits GA, Bartsch GE, Stamler J. Chapter 4. Method
issues in dietary data analyses in the multiple risk
factor intervention trial. Am J Clin Nutr 1997;65
(Suppl):211S–27S.
EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 273 EFFECT OF MATERNAL PROTEIN-ENERGY SUPPLEMENTATION ON ADOLESCENT BLOOD PRESSURE 273